About
Outlook Therapeutics
OTLK.US
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
Profile
- Company Name
- Outlook Therapeutics, Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- September 30
- Website
- outlooktherapeutics.com